A blog about what is new (and old) in the world of active implantable medical devices 

Facebook Twitter Gplus Flickr LinkedIn YouTube RSS
magnify
Home Treated Conditions Archive for category "Obesity"
formats

EnteroMedics Reports Maestro Obesity Study Showing 25% Reduction in Excess Weight

EnteroMedics reported new clinical trial data for its Maestro system, which is designed to treat obesity through vagus nerve stimulation. The company said that its Maestro RC system lost 25% of their excess weight, or 10% of their total body weight, after 18 months. Patients who received a sham implant lost 12% of excess weight,

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on EnteroMedics Reports Maestro Obesity Study Showing 25% Reduction in Excess Weight  comments 
formats

EnteroMedics Submits PMA of the Maestro VBLOC System for Treatment of Obesity

EnteroMedics  reported that it has submitted its pre-market approval application for FDA review of its Maestro Rechargeable System’s VBLOC vagal blocking therapy as a treatment for obesity This is an important step for an implantable device company that faced very tough times in 2009 after its US clinical trial failed to meet a critical effectiveness

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on EnteroMedics Submits PMA of the Maestro VBLOC System for Treatment of Obesity  comments 
formats

EnteroMedics Reports $123k Revenue from Sales of its Maestro RC IPG for Treatment of Obesity

Today EnteroMedics recorded revenue for the first time since it was incorporated nearly eight years ago. The company reported revenue of about $123,000 in the first quarter of the year from the sale of its Maestro RC implantable vagus nerve stimulation system for treating obesity. Revenue was generated through sales by its distribution partner in Australia.

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on EnteroMedics Reports $123k Revenue from Sales of its Maestro RC IPG for Treatment of Obesity  comments 
formats

Leptos Biomedical’s Splanchnic Nerve Stimulation For Treatment Of Obesity (2002-2010)

Leptos Biomedical was founded in Fridley, MN in 2002 by Dr. John D. Dobak.   Leptos intended to develop an implantable device to stimulate the greater splanchnic nerve, that was hoped would  result in reduced food intake and increased energy expenditure. In February 2010 Leptos announced its closure.  Reasons were not provided, but it has been suggested that the decision

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Leptos Biomedical’s Splanchnic Nerve Stimulation For Treatment Of Obesity (2002-2010)  comments 
formats

Intrapace Abiliti Gastric Stimulator for the Treatment of Obesity

Intrapace was founded in Mountain View, CA by Mir Imran in 2001 to develop an implantable system for the treatment of obesity.  Once implanted and activated, the Abiliti system is designed to detect when a person consumes food or drink. When food or drink is detected, the system delivers a series of low-energy electrical impulses to the

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
1 Comment  comments 
formats

Transneuronix Transcend IPG for Obesity Treatment

Transneuronix, Inc. was founded in 1995 and was based in Mount Arlington, New Jersey. It was acquired by Medtronic in 2005. Before its acqusition by Medtronic, Transneuronix developed the Transcend, an implantable gastric stimulator device for the treatment of obesity by electrical stimulation of the stomach.  Later, Medtronic developed the Transcend II IPG.

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
1 Comment  comments 
formats

EnteroMedics’ Maestro RC Vagus Nerve Stimulator for Obesity Management

EnteroMedics Inc. was founded in St. Paul, MN in 2002 to develop a platform for vagus-nerve stimulation, primarily for obesity management.  In March 2011 EnteroMedics received the CE Mark for its second-generation system – the Maestro RC. The EnteroMedics Maestro RC device delivers VBLOC® vagal blocking therapy to through laparoscopically implanted leads to intermittently block the vagus nerves using

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
1 Comment  comments 
formats

AIMD Companies Founded by Yossi Gross

Yossi Gross (born February 5, 1947) is an Israeli medical device innovator and entrepreneur. His medical-device companies are incubated through Rainbow Medical. Currently, the following companies led by Yossi Gross are focusing on active implantable medical devices: BetaStim, developing a new neurostimulation treatment for diabetes Brainsgate, developing an implantable device for acute stroke treatment and brain

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on AIMD Companies Founded by Yossi Gross  comments 
formats

AIMD Companies Founded by Dr. Shlomo Ben-Haim

Dr. Shlomo Ben-Haim has held faculty appointments as a Professor of Medicine, Physiology and Biophysics, at both Harvard University and the Technion – Israel Institute of Technology. His formal education is in the fields of nuclear physics, mathematics, biomedical engineering, philosophy, and medicine. Dr. Ben-Haim has published his research in over 100 scientific papers, in

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on AIMD Companies Founded by Dr. Shlomo Ben-Haim  comments 
formats

AIMD Companies Founded by Mir A. Imran (InCube)

Mir A. Imran (born 1956, Hyderabad, India), is an Indian entrepreneur and venture capitalist. Imran has formed 19 companies since the early 80s and holds over 140 patents.  He is the founder and Chairman of InCube Laboratories, Inc., a research laboratory and business incubator for medical and technology companies Currently, four InCube companies are focusing

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on AIMD Companies Founded by Mir A. Imran (InCube)  comments 
formats

Tantalus II System for Treating Metabolic Syndrome

MetaCure’s TANTALUS II device is an advanced implantable electrical stimulator used to apply gastric stimulation. It works by enhancing the activity of gastric muscles only when the patient eats, which modifies hormone secretion, favorably affecting glucose and fat metabolism. At the same time, the stimulation causes the patient to feel satiated sooner and consume less

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Tantalus II System for Treating Metabolic Syndrome  comments